Advanced Medical Solutions Group (AMS) Trading Update summary

Financial performance and outlook

• Revenue for H1 2025 expected at approximately £110 million, up from £68.0 million in H1 2024.

• Adjusted EBITDA projected between £24.0–£24.5 million, compared to £18.2 million in H1 2024.

• Performance aligns with expectations, supporting confidence in meeting full-year consensus forecasts.

• Interim results announcement scheduled for 17 September 2025.

Strategic initiatives and integration

• Integration of Peters Surgical and Syntacoll is progressing well, with early commercial synergies boosting surgical sales.

• Restructuring of the Woundcare business completed by March, leading to improved margins from Q2.

• Focus remains on delivering longer-term, significant synergies from recent acquisitions.

• Core surgical product portfolio continues to drive robust growth.

Business overview and operations

• Specializes in tissue-healing technologies, offering surgical products and wound care dressings under multiple brands.

• Products are manufactured across several countries and sold globally through partners and direct sales.

• Seven acquisitions since 2019 have expanded capabilities in surgical and wound care segments.

• Employs over 1,500 staff and operates R&D hubs in the UK, Ireland, Germany, France, and Israel.